Attaining, Maintaining, and Sustaining Healthcare Systems in a Changing World: The Role of HTA

The HTAi 2020 Annual Meeting will focus on the roles that Health Technology Assessment (HTA) can play in improving patient-relevant outcomes while sustaining healthcare systems.

Attaining universal health coverage (UHC) is a pressing issue for many countries, particularly those with lower and middle incomes. HTA is a recognized tool for priority setting, making evidence-based resource allocation decisions, and developing benefits packages to help achieve UHC. We also know that in these healthcare systems and in countries that have achieved UHC, HTA plays an ongoing role in progressing UHC and the sustainability of the healthcare systems.

However, current developments are challenging and changing treatment and epidemiological paradigms. Prominent examples include ‘disruptive’ technologies, such as cell and gene therapy, and the incoming data tide, including increased utilization of existing real-time data sources (like wearables), and modern technologies such as artificial intelligence, blockchain, and big data architecture.  The consequences for HTA and the need to adapt is apparent, and must be faced globally to ensure the continued sustainability of healthcare systems in 2020 and beyond.

HTAi invites you to join the leading minds in HTA to discuss and debate the role of HTA in attaining, maintaining, and sustaining healthcare systems in a changing world.

POST-Event Survey

We hope you enjoyed HTAi's 2020 Virtual Annual Meeting. If you have a moment, we would appreciate hearing your feedback on the event. Please click the link below to proceed to the survey.

About HTAi

Health Technology Assessment international (HTAi) is the global scientific and professional society for everyone who produces, uses, or encounters Health Technology Assessment to support optimal policy and decision making.  Its mission is to support the growth of the HTA community by providing a neutral, global forum for the exchange of information, methods and expertise. With members from over 60 countries and across six continents, HTAi is a thriving global network.

Our members regularly participate in MeetingsPolicy Fora and Interest Groups. HTAi also provides access to a variety of resources including the International Journal of Technology Assessment in Health Care (IJTAHC).

HTAi also supports national and regional initiatives for countries embarking on implementing HTA programs, and works to connect members with common interests.

HTAi is governed by an elected Board of Directors that is supported by an Executive Committee, several Advisory Committees and a Secretariat.

HTAi Annual Meeting

Held each year in June, the HTAi Annual Meeting is a key international gathering for sharing latest research, advancing discussions in policy and methods, and building global networks.

The Annual Meeting supports the mission of HTAi to promote the development, understanding and use of HTA around the world as a means of fostering innovation and effective use of resources in health care.

The Annual Meeting provides a complimentary and unique environment to develop international collaborations and face the challenges posed in our local and global health systems today. Through continuous growth and expansion, the meeting consistently draws together a large number of researchers, agencies, policy makers, industry, academia, health service providers and patients/consumers, and welcomes all interested parties, to share information and best practices from cutting-edge technologies to system development with a focus on the impact on patient care.

The Annual Meeting provides an environment for attendees to interact with colleagues from different countries, exchange ideas and expertise, reconnect with old friends and grow new collaborations and supportive and lasting connections.

HTAi Global Policy Forum

HTAi’s mission is to support and promote the development, communication, understanding and use of HTA around the world as a scientifically based means of promoting the introduction of effective innovations and the effective use of resources in health care.

The HTAi Global Policy Forum provides a unique opportunity for senior people from public and private sector organizations using HTA to support decisions or recommendations about product development and coverage to meet one another, members of the HTAi Board, and invited international experts, for strategic discussions about the present state of HTA, its development and implications for health care systems, industry, patients and other stakeholders. The aim of the Forum is to provide an environment where senior people can engage in strategic discussions informed by the perspectives of their different organizations without the constraints associated with discussions of specific products or organizational policies.

Membership in the HTAi Global Policy Forum is by application. From time to time (typically around April each year) HTAi issues calls for Expressions of Interest in joining the Global Policy Forum. Final decisions on membership are made by the HTAi Board of Directors on advice from the Global Policy Forum Committee.

HTAi Interest Groups (IGs)

HTAi’s Interest Groups serve as hubs for sharing international experiences and expertise among HTA users and producers worldwide.

Over time, HTAi members have established and strengthened our IGs as a way of achieving a thriving international society serving as a primary professional and scientific forum for all those who undertake and use HTA in health care, business, government, academic institutions and consultancies.

The Interest Groups provide a unique environment for the members of HTAi to network and share information throughout the year.  Interest Group members share topics updates, participate in the development of new research and useful materials, conduct meetings, workshops, training sessions and more.

Interest Groups are the hubs of HTA producers or users, ranging from 50 to 300 Society members per group and comprise approximately 60 percent  of the Society’s membership. Involvement in IGs is open to all Society members across different nations, fields of interest and expertise, allowing the HTA community to share information and collaborate on projects of mutual interest.

International Scientific Program Committee (ISPC)

The International Scientific Program Committee (ISPC) of the Annual Meeting is responsible for developing the Scientific Program of the HTAi Annual Meeting. The ISPC is a standing committee which is selected annually.


View the ISPC Terms of Reference

Committee Co-Chairs

Dr. Wei Fu

China National Health Development Research Centre, China

Dr. Yonghao Gui

Fudan University, China

Prof. Brendon Kearney

Health Policy Advisory Committee on Technology (HealthPACT), Australia


Prof. Yingyao Chen

Fudan University, China

Executive Group

Prof. Jeonghoon Ahn
Ewha Womans University, Korea

Dr. Wija Oortwijn
Radboud University Medical Center, Netherlands

Kenneth Bond
Institute of Health Economics, Canada

Prof. Fiona Pearce
Ministry of Health, Singapore

Adrian Griffin
Johnson & Johnson, United Kingdom

Dr. Janney Wale
Patient Representative, Australia

Committee Members

Dr. Wendy Joy Babidge
The Australian Safety and Efficacy Register of New Interventional Procedures – Surgical (ASERNIP-S), Australia

Richard Charter
BD Europe, Switzerland

Rosmin Esmail
Alberta Health Services, Canada

Prof. Rabia Kahveci
SAFEMed, Ukraine

Prof. Maarten Postma
University of Groningen, Netherlands

Prof. Asrul Akmal Shafie
Universiti Sains Malaysia, Malaysia

Catherine Voutier
Royal Melbourne Hospital, Australia

Dr. Hector Castro
Management Sciences for Health, Columbia

Prof. Americo Cicchetti
Universita Cattolica del Sacro Cuore, Italy

Dr. Iñaki Gutierrez-Ibarluzea
Ministry for Health, Spain

Dr. Pattara Leelahavarong
The Health Intervention and Technology Assessment Program, Thailand

Dr. Jasmine Pwu
Ministry of Health and Welfare, Chinese Taipei

Dr. Jitendar Sharma
Kalam Institute of Health Technology, India

Rebecca Trowman
Telethon Kids Institute, Australia

Dr. Lu Ye
Fudan University, China

Dr. Kalipso Chalkidou
Imperial College London, United Kingdom

Prof. Simon Dixon
University of Sheffield, United Kingdom

Denny John
The Campbell Collaboration, India

Dr. Nguyen Khanh Phuong
Health Strategy and Policy Institute, Vietnam

Francis Ruiz
Imperial College of London, United Kingdom

Prof. Lizheng Shi
Tulane University, United States

Dr. Feng Xie
McMaster University, Canada

Prof. Kun Zhao
China National Health Development Research Centre, China

Main Theme

Attaining, Maintaining, and Sustaining Healthcare Systems in a Changing World: The Role of HTA

The HTAi 2020 Annual Meeting will focus on the roles that Health Technology Assessment (HTA) can play in improving patient-relevant outcomes while sustaining health systems.

Attaining Universal Health Coverage (UHC) is a pressing issue for many countries, particularly those with lower and middle incomes. HTA is a recognized tool for priority setting, making evidence-based resource allocation decisions, and developing benefits packages to help achieve UHC. We also know that in these health systems and in countries that have achieved UHC, HTA plays an ongoing role in progressing UHC and sustainability of the healthcare systems.

However, current developments are challenging and changing treatment and epidemiological paradigms. Prominent examples include ‘disruptive’ technologies, such as cell and gene therapy, and the incoming data tide, including increased utilization of existing real-time data sources (like wearables), and modern technologies such as artificial intelligence, blockchain, and big data architecture.  The consequences for HTA and the need to adapt is apparent, and must be faced globally to ensure the continued sustainability of health systems in 2020 and beyond.

HTAi invites you to join the leading minds in HTA to discuss and debate the role of HTA in attaining, maintaining, and sustaining health systems in a changing world.


The Role of HTA in Achieving and Progressing Universal Health Coverage

Universal Health Coverage (UHC) has been acknowledged as a priority goal of many health systems, with the recognition that UHC improves the health of a population and reduces health inequalities. Furthermore, there is general consensus that healthier populations are more productive, take less sick leave and demand less healthcare services resulting in economic benefits on a long-term basis. The importance of achieving UHC is reflected in the consistent calls by the World Health Organization (WHO) for member states to implement systems that promote access to quality health care and provide households with the needed protection from the catastrophic consequences of out-of-pocket (OOP) health-related payments. Progress towards UHC is a continuous process that changes in responses to shifting demographic, epidemiological and technological trends, as well as a population’s expectations.

HTA is recognized as an important approach in setting benefits packages for UHC and in answering other key questions that policy makers are left to grapple with after the commitment to UHC is made. HTA can address central issues: what services should be made available, and under what conditions? In the context of fixed and restricted budgets, where it is necessary to prioritize, should more (priority) services be included? Should coverage of existing (priority) services be expanded or excluded? Should co-payments of existing (priority) services be reduced? When making these decisions, social, legal ethical, and socio-economic issues need to be addressed in a meaningful deliberative manner to enhance public accountability.

The need to perform HTA is higher where resources are limited. For example, in countries with a fragile economic state, HTA can be used to define basic benefit packages; emergency kits and for disaster planning. For low-income countries with low levels of UHC, HTA can be used to define essential medicines and other interventions packages (including vaccinations, prevention and some treatments), for middle-income countries with medium UHC, HTA can then be used to define extensions to benefits packages including treatment of (non-communicable) diseases and for specific populations. For high-income countries with a high level of UHC, HTA can be used to define full-benefits packages (including home care, palliative care and diagnostic services and innovative technologies) and to reassess or disinvest from services.

There are also many hurdles to be overcome in relation to healthcare and human resource capacity and access to health services. These relate to scope of services, quality, cost, and governance of a specific context. HTA is an effective tool to unravel/unveil these barriers by answering questions about a health technology or service, in terms of availability, accessibility, equity, and affordability in that specific context. However, HTA is not the only solution to achieving and progressing UHC in any health system. HTA should be considered as one part of the complex health ecosystem within a political system with local customs, cultural and environmental issues always being considered when prioritizing services.

Based on the above description, the plenary session will consist of:

  • a short overview of Universal Health Coverage, what’s in and what’s out and the possible role of HTA (e.g. priority setting, benefits package listings, horizon scanning, reassessment);
  • using HTA to inform the development and prioritization of basic and essential healthcare (e.g. looking at the cost effectiveness of integrated clinical pathways and benefit packages specific to local contexts);
  • explore the crucial elements that are required to conduct UHC-focused HTA that considers the appropriateness to socio-political factors (e.g. culture adaption to use evidence for decision making and appropriate and meaningful patient/public involvement);
  • consider what works well when using HTA in the context of achieving UHC; acknowledging that there is “not one size that fits all”.


How to Adapt HTA to Address Technologies that are ‘Disrupting’ Health Systems

There are an increasing number of emerging innovations that have a high potential to be “disruptive.” That is, technologies that are representing fundamentally, and possibly unexpected, new modes of clinical practice or service improvement that will disrupt or overturn the traditional methods and practices in health systems. They include but are not limited to potentially curative therapies such as, gene therapies, somatic-cell therapies, and tissue-engineered therapies. Examples include Chimeric Antigen Receptor (CAR) T-cell therapies, gene editing using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR), preventative therapy for Alzheimer’s Disease and genetic diagnostic tests.

It is often challenging to adequately estimate the value of these disruptive technologies using current HTA frameworks and methodologies. As these typically ‘one-shot,’ expensive treatments will most likely be compared to a lifetime of existing treatments, the traditional HTA paradigms will be tested. This may include increased safety concerns (certainty of treatment effect and potential for adverse events); assessing and paying for value, and appropriate incorporation of ethical, legal, social, and patient/consumer issues and concerns. A number of policy issues may impact current HTA frameworks and methodologies in considering these technologies, such as: global differences in regulatory, patenting and pricing mechanisms; the manufacturing and subsequent organization of service delivery; and balance of risk versus access to innovative technologies (particularly in the context of a sustainable health system providing Universal Health Coverage).

Recognizing the large number of disruptive technologies under development, consideration needs to be given to whether current HTA frameworks are appropriate for the evaluation of these potentially ground-breaking technologies. Critical assessment of the current HTA frameworks with regards to the specific characteristics of these technologies and continued dialogue will be key to ensuring appropriate market access and for informing coverage decisions.

This plenary session aims to gain insights and generate discussion on the following areas:

  • Methodological uncertainties and the associated consequences that are particularly relevant to the assessment of disruptive technologies, including HTA best practices for implementation (or knowledge translation) and evaluation of these technologies;
  • Collaboration between HTA agencies on sharing experiences, knowledge gained, and lessons learned
  • Whether horizon scanning systems can play a more systematic role in fostering cross-stakeholder interactions, encouraging the preparation of health systems in the appropriate uptake of disruptive and potentially costly technologies;
  • How and when (and if) HTA processes could be adapted specifically for these technologies to align with different regulatory and/or reimbursement systems;
  • How the sustainability of Universal Health Coverage (UHC) and health systems can be maintained while ensuring appropriate access to these high-cost, yet potentially ground-breaking technologies;
  • The pressing ethical, legal, social, and policy implications regarding the introduction and adoption of these technologies;
  • Whether patient, citizen, and broader stakeholder involvement processes should be adapted to help promote the development, assessment, diffusion, and adoption of these technologies.


Incoming Tides and What it Means for HTA; the Rise of Real-World Evidence, ‘Big Data’, and Artificial Intelligence.

In the last few years, real-world evidence (RWE), ‘big data’, and Artificial Intelligence (AI) have been rapidly increasing in terms of prevalence and applications. The following definitions can be considered:

  • RWE is evidence derived from the analysis of real-world data (RWD; observational or administrative data) that can provide information on the routine delivery of health care and the health status of a population;
  • Big data is an evolving term that describes a large volume of a variety of data (structured or unstructured) that has the potential to be mined for information;
  • AI is the simulation of human intelligence processes by machines, including learning, reasoning, and self-correction. In the medical context, AI has the potential to be used to exploit datasets in the diagnosis, treatment, and prediction of outcomes in many clinical scenarios.

The rise in these data collection and analysis modalities is already impacting health care delivery and subsequently HTA, with the potential to reshape health care practice around the world. However, these increased possibilities also bring a number of challenges. The quality and acceptability of the data being collected, the governance and accountability surrounding the data (including consent for data collection and usage) and transference of data securely across stakeholder groups are all key issues. Principles on how and when RWE, big data, and AI can be used to inform decision-making (both at the clinical level and also in the context of HTA) all need to be deliberated and openly discussed.

Applications of AI, based on big data, are already being used for assisting clinical decision making, radiological and pathological analysis, early prediction, monitoring of health risks, and health insurance fraud detection. The possible increase in predictive accuracy is a result of potentially complex algorithms that can sometimes appear to be “black boxes”; it is important that comprehensive evaluations and input from all stakeholders (particularly from the viewpoint of patients and citizens) is undertaken. AI is also being integrated into HTA conduct (including, but not limited to, horizon scanning and systematic literature searches). As a result, the HTA community need to urgently consider how this will affect clinical and HTA workforces, and how to effectively collaborate with technology developers and platforms. It is also imperative that preparation for the influx of big data, RWE, and AI continues; including a deeper understanding of the potential ‘disruption’ to sustainable health systems.

Given the breadth of the full topic, the plenary session will focus on AI including:

  • The implication of AI in health systems; how AI is being used with case studies of applications of AI in clinical practice now and potentially in the future (e.g. clinical decision-making and diagnosis in oncology, neurology, diabetic retinopathy, radiology, cardiology).
  • Where (big) data comes from to inform and develop AI algorithms, who owns the data, what factors were taken into consideration, experience in developing and testing algorithms.
  • How AI can and should be transparently evaluated, the risks of AI getting treatment/diagnostic algorithms wrong or skewed and biased, and the way HTA may need to adapt.
  • The use of AI in HTA and the impact on the HTA community and workforce.
  • Quality, ethical, and regulatory implication of AI, particularly from the patient perspective.


Please Note:

All times indicated in the Agenda are in Mountain Daylight Time (MDT). MDT is -6 Hours of UTC. Please click below for a conversion application.


View the HTAi 2020 Virtual Annual Meeting abstracts below. The poster gallery can be viewed through the link below. Just click "View" next to the Poster Gallery options.

Click Here


View the HTAi 2020 Virtual Annual Meeting abstracts.

2020 Host Organizations

Fudan University and the Key Lab of Health Technology Assessment, National Health Commission (Fudan University) (KLHTA)

Fudan University was established in 1905 in Shanghai, China, and is one of the top universities in China.  On April 27, 2000, Shanghai Medical University (established in 1927) merged with Fudan University, evolving into a renowned research university with diverse academic disciplines. Such disciplines include Philosophy, Economics, Law, Education, Literature, History, Sciences, Engineering, Medical Sciences, Management, and Art. Shanghai Medical College, Fudan University is respected for its rigorous medical curriculum and high research capacity. There are seventeen affiliated hospitals, including Zhongshan Hospital and Huashan Hospital. The College also has nine National Health Commission (NHC) key labs, one of which is KLHTA.

KLHTA is based at School of Public Health, Fudan University. It is China’s first HTA agency, and one of the most active agencies in the field of HTA in China. Its goal is to strengthen the impact of HTA on China’s health system through collaboration with policy- and decision-makers. It aims to provide high quality HTA evidence to inform health policy and clinical decision making, to advance talent training and disciplinary development, and to promote knowledge translation. KLHTA is devoted to scientific research, education and training, consultation, exchanges, and collaboration in the field of HTA. KLHTA’s major areas of research are:

  • Methodology research: Build standard procedures and methodological models of HTA and study HTA research methods pertaining to the use of big data;
  • Assessment of Medical Technology: Conduct scientific assessments of medical technologies to support clinical decision making;
  • Assessment of Public Health Technology: Conduct systematic assessments of public health interventions to support decision making;
  • Assessment of Environmental Hazard and Interventions: Identify environmental health risks, conduct research to design and evaluate strategies of risk prevention and control, and inform the design of health impact assessment protocols;
  • Translational Research: Design tools and strategies to support knowledge translation in China’s health policy environment;
  • Assessment of Health Policies and Systems: Evaluate major policies on health technology at a macro level.

KLHTA is solicited frequently to provide consultation and decision-making advice to many departments of NHC and the Shanghai municipal government. In terms of education and training, KLHTA offers master’s and PhD programs in HTA at Fudan University. In May 2017, KLHTA released an HTA online course in Chinese on China’s best Massive Open Online Course (MOOC) platform.

Internationally, KLHTA is a WHO Collaborating Centre for Health Technology Assessment and is also a member of HTAsiaLink.


China National Health Development Research Centre (CNHDRC)

The China National Health Development Research Center (CNHDRC) is a health think-tank established by the National Health Commission of People’s Republic of China (NHC) and has made remarkable progress on embedding health technology assessment (HTA) into its health system. The main responsibilities of CNHDRC include:

  • Conducting research on the national health policy and development planning
  • Developing health technology assessment mechanisms and promoting methodology development
  • Conducting health economics studies
  • Evaluating the functional oriented health service delivery system
  • Formulating risk assessment and theoretical research
  • International exchanges

Numerous HTA projects have been conducted upon the request of national and provincial policy-makers and other health-related stakeholders for guiding their decision making and establishing incentive policies to innovative technology industries:

Medical Devices:

  • Rapid HTA projects on select advanced and costly medical technologies


  • Economic evaluation on infectious disease drugs
  • National Essential Drug List
  • National Reimbursement Drug List


  • Hemodialysis
  • Gene therapies & Somatic-cell therapies (Chimeric Antigen Receptor T-cell, Immune Cell Therapy)

Public Health:

  • Diagnosis and screening tests
  • Vaccines
  • Public Health Services/Package (Maternal and Child Health)

Policy Evaluation:

  • The Health System Planning
  • The Health System Quality Control
  • Healthy China

Facing rising health expenditures amidst growing non-communicable disease burdens, the National Center for Medicine and Health Technology Assessment, which was endorsed by the NHC, launched in 2018 under the CNHDRC. The national HTA agency is responsible for assessing new medicines, informing decisions on what goes on the National Essential Medicines List (EML), and guiding regional policy to ensure that priority-setting is based on value.

Various international organizations, including WHO, World Bank, UNICEF, IDRC in Canada, NICE; NGOs such as the Bill & Melinda Gates Foundation; universities such as Imperial College, University of Toronto, University of Queensland, Australia; and  Networks like HTAsialink and ISPOR, have been closely linked and have collaborated with CNHDRC to support quality improvements, care integration, efficiency and effectiveness, and the development of Health Technology Assessment in China.

2020 Sponsors

PLATinum Sponsors

At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Today Biogen has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, commercializes biosimilars of advanced biologics and is focused on advancing research programs in multiple sclerosis and neuroimmunology, neuromuscular disorders, movement disorders, Alzheimer’s disease and dementia, ophthalmology, immunology, neurocognitive disorders, acute neurology and pain.

Edwards Lifesciences, based in Irvine, California, is the global leader in patient-focused medical innovations for structural heart disease, as well as critical care and surgical monitoring. Driven by a passion to help patients, the company collaborates with the world’s leading clinicians and researchers to address unmet healthcare needs, working to improve patient outcomes and enhance lives.

For more than a century, MSD, a leading global biopharmaceutical company, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases. MSD is a trade name of Merck & Co., Inc., with headquarters in Kenilworth, N.J., U.S.A. Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programs and partnerships. Today, MSD continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world – including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer’s disease and infectious diseases including HIV and Ebola. For more information, visit and connect with us on TwitterLinkedIn and YouTube.

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier and more productive lives. Since 2000, PhRMA member companies have invested more than $900 billion in the search for new treatments and cures, including an estimated $79.6 billion in 2018 alone.

Connect with PhRMA
For information on how innovative medicines save lives, please visit:

Diamond Sponsors

Novartis is re-imagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development.

Novartis products reach more than 750 million people globally and we are finding innovative ways to expand access to our latest treatments. About 109,000 people of more than 140 nationalities work at Novartis around the world.


Vifor Pharma Group is a global pharmaceuticals company headquartered in Switzerland. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company develops, manufactures and markets pharmaceutical products for precision patient care and strives to help patients around the world with severe and chronic diseases lead better, healthier lives. It consists of the following companies: Vifor Pharma; the joint company Vifor Fresenius Medical Care Renal Pharma; Relypsa; and OM Pharma.

GOld Sponsors

Set up in 2009 at the Università Cattolica del Sacro Cuore (Rome campus) as a result of a scientific collaboration between the faculty of Economics and the faculty of Medicine and Surgery, ALTEMS operates within the field of Economics and Healthcare management and offers qualification-based training at various stages in the professional development of people employed in the field of private and public healthcare. The mission of ALTEMS, in which its fundamental purposes are stated, is “to plan, organise and deliver post-graduate and executive training programmes within the fields of economics and health care management.

Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.

With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe. Sanofi, Empowering Life

Health Technology Wales has been established to support a strategic, national approach to the identification, appraisal and adoption (including disinvestment) of non-medicine health technologies into health and care settings.  This includes medical devices, surgical procedures & a range of other interventions e.g. psychological therapies & rehabilitation.

HTW is an independent, arms-length organisation that will deliver authoritative evidence-informed advice about the value for money of non-medicine health technologies to improve patient outcomes for all patients in Wales.

HTWs works in three main areas – identification, appraisal and adoption of non-medicine technologies – to help create a common understanding of value in NHS Wales and to optimise the use of health interventions.

To deliver these functions HTW is working with health, academic, patient and industry bodies in Wales and internationally.

Family-owned since 1885, Boehringer Ingelheim is one of the top 20 pharmaceutical companies worldwide.

Some 50,000 employees create value through innovation in the business areas human pharmaceuticals, animal health and biopharmaceuticals. In our role as our patients’ partner we concentrate on researching and developing innovative medicines and therapies that can improve and extend patients’ lives.

Contact Us

For all information related to the HTAi 2020 Annual Meeting, please email the Annual Meeting Team at:

Please note that the business hours of the Annual Meeting Team are 8:00 to 16:00 MDT, (14:00 – 22:00 UTC/GMT) Monday through Friday.


HTAi Secretariat
1200, 10405 Jasper Avenue
Edmonton, Alberta, Canada
T5J 3N4

P: +1 780 448 4881
F: +1 780 448 0018

Stay in Touch